Skip to main content
. Author manuscript; available in PMC: 2011 Aug 9.
Published in final edited form as: Cancer Cell. 2010 Aug 9;18(2):160–170. doi: 10.1016/j.ccr.2010.06.014

Figure 4. The therapeutic effect of anti-neu antibody depends on endogenous danger signals.

Figure 4

A) WT and Myd88−/− BALB/c mice (n=5–7/group) were injected s.c. with 4 × 105 TUBO cells and treated with 100 μg of anti-neu (α-neu) or isotype control (Ctrl) antibody on days 21 and 28. *, p<0.01 compared to anti-neu antibody treated Myd88−/− mice. One of two experiments is shown. B) TUBO-bearing WT BALB/c mice (n=4/group) were treated with 100 μg of anti-neu antibody (α-neu) and 100 μg of neutralizing anti-HMGB-1 antibody on days 14 and 21. **, p < 0.005, compared to anti-HMGB-1 antibody-treated group. One of four experiments is shown.